Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...